The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback